Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Longitudinal chemodenervation effects of botulinum toxin A and impact of physical activity
2017-003117-25Phase 4Completed
- Sponsor
- Medical University of Vienna
- Start
- Apr 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of botulinum toxin type A in spastic hemiparesis and upper extremity spasticity, sponsored by Medical University of Vienna. Primary endpoint: Longitudinal monitoring of denervation edema and correlation with muscle weakness/spasticity reduction. Started Apr 2018; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
spastic hemiparesisupper extremity spasticity
Beyond the preview
Go deeper on 2017-003117-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003117-25.